Ray Animesh, Kunhiraman Haritha, Perera Ranjan J
Riggs School of Applied Life Sciences, Keck Graduate Institute, Claremont, CA, United States.
Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, United States.
Front Oncol. 2021 Feb 8;10:628367. doi: 10.3389/fonc.2020.628367. eCollection 2020.
Cancer initiation, progression, and metastasis leverage many regulatory agents, such as signaling molecules, transcription factors, and regulatory RNA molecules. Among these, regulatory non-coding RNAs have emerged as molecules that control multiple cancer types and their pathologic properties. The human microRNA-211 (MIR211) is one such molecule, which affects several cancer types, including melanoma, glioblastoma, lung adenocarcinomas, breast, ovarian, prostate, and colorectal carcinoma. Previous studies suggested that in certain tumors MIR211 acts as a tumor suppressor while in others it behaves as an oncogenic regulator. Here we summarize the known molecular genetic mechanisms that regulate gene expression and molecular pathways that are in turn controlled by MIR211 itself. We discuss how cellular and epigenetic contexts modulate the biological effects of MIR211, which exhibit pleiotropic effects. For example, up-regulation of expression down-regulates Warburg effect in melanoma tumor cells associated with an inhibition of the growth of human melanoma cells , and yet these conditions robustly increase tumor growth in xenografted mice. Signaling through the DUSP6-ERK5 pathway is modulated by MIR211 in BRAF driven melanoma tumors, and this function is involved in the resistance of tumor cells to the BRAF inhibitor, Vemurafenib. We discuss several alternate but testable models, involving stochastic cell-to-cell expression heterogeneity due to multiple equilibria involving feedback circuits, intracellular communication, and genetic variation at miRNA target sties, to reconcile the paradoxical effects of MIR211 on tumorigenesis. Understanding the precise role of this miRNA is crucial to understanding the genetic basis of melanoma as well as the other cancer types where this regulatory molecule has important influences. We hope this review will inspire novel directions in this field.
癌症的起始、进展和转移涉及多种调控因子,如信号分子、转录因子和调控RNA分子。其中,调控性非编码RNA已成为控制多种癌症类型及其病理特性的分子。人类微小RNA-211(MIR211)就是这样一种分子,它影响多种癌症类型,包括黑色素瘤、胶质母细胞瘤、肺腺癌、乳腺癌、卵巢癌、前列腺癌和结直肠癌。先前的研究表明,在某些肿瘤中MIR211起肿瘤抑制作用,而在其他肿瘤中它表现为致癌调节因子。在这里,我们总结了调控基因表达的已知分子遗传机制以及反过来受MIR211自身控制的分子途径。我们讨论了细胞和表观遗传背景如何调节MIR211的生物学效应,MIR211具有多效性。例如,MIR211表达上调会下调黑色素瘤肿瘤细胞中的瓦伯格效应,这与抑制人类黑色素瘤细胞生长相关,但这些条件却能显著增加异种移植小鼠中的肿瘤生长。在BRAF驱动的黑色素瘤肿瘤中,MIR211通过DUSP6-ERK5途径调节信号传导,并且这种功能与肿瘤细胞对BRAF抑制剂维莫非尼的抗性有关。我们讨论了几种替代但可测试的模型,这些模型涉及由于涉及反馈回路、细胞内通讯和miRNA靶位点的遗传变异的多重平衡导致的随机细胞间表达异质性,以解释MIR211对肿瘤发生的矛盾效应。了解这种miRNA的确切作用对于理解黑色素瘤以及其他受这种调控分子影响的癌症类型的遗传基础至关重要。我们希望这篇综述能为该领域带来新的方向。